Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

TapImmune Inc (NASDAQ:TPIV)

4.12
Delayed Data
As of 3:50pm ET
 +0.0491 / +1.21%
Today’s Change
3.90
Today|||52-Week Range
11.64
-42.81%
Year-to-Date
SECTOR
Consumer Services
INDUSTRY
Other Consumer Services
MARKET CAP
$34.1M

Company Description

TapImmune, Inc. is focusing on immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer. It develops vaccines for breast cancer, colorectal cancer, ovarian cancer and non-small cell lung cancer. The company was founded in 1991 and is headquartered in Jacksonville, FL.

Contact Information

TapImmune, Inc.
50 North Laura Street
Jacksonville Florida 32202
P:(904) 516-5436
Investor Relations:
(206) 504-7267

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Glynn WilsonChairman, CEO, Secretary & CAO
John N. BonfiglioPresident, Chief Operating Officer & Director
Michael J. LoiaconoCFO, Secretary, Treasurer & CAO
Mark ReddishDirector & Vice President-Development